Chaethana Yalamanchili, MD
Emergency Medicine · Dallas, TXNPI 1740490325
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $510 and has fallen 63.6% since, to $186 in 2025. Among emergency medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$169
- Neurocrine Biosciences, Inc.$141
- AstraZeneca$116
- UCB, Inc.$85
- AbbVie$58
- AVEO Pharmaceuticals, Inc.$57
- plus $477 from 16 others
What the payments were for
- Food & beverage$1,102100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $169 |
| Neurocrine Biosciences, Inc. | 5 | $141 |
| AstraZeneca(2 entities) | 4 | $116 |
| UCB, Inc. | 4 | $85 |
| AbbVie | 2 | $58 |
| AVEO Pharmaceuticals, Inc. | 3 | $57 |
| Lilly USA, LLC | 3 | $54 |
| Averitas Pharma Inc. | 2 | $51 |
| Genmab U.S., Inc. | 2 | $49 |
| CSL Behring | 2 | $48 |
| SK Life Science, Inc. | 2 | $45 |
| Merz Pharmaceuticals, LLC | 1 | $26 |
| Incyte Corporation | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
How this compares
$1,102 in reported general payments places this provider in the 95th percentile of 3,952 emergency medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 14 | $8,322 |
| Fentanyl | 63 | $7,060 |
| Morphine Sulfate ErMorphine Sulfate | 61 | $1,964 |
| Morphine Sulfate | 48 | $1,927 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 63 | $1,731 |
| Naloxone Hcl | 28 | $1,697 |
| Mirtazapine | 59 | $879 |
| Ondansetron OdtOndansetron | 38 | $792 |
| Olanzapine | 47 | $736 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $717 |
| Oxycodone Hcl | 41 | $702 |
| Duloxetine Hcl | 68 | $587 |
| Gabapentin | 41 | $472 |
| Pregabalin | 26 | $361 |
| Hydromorphone Hcl | 20 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $54 | $73647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,952 emergency medicine providers in Texas.
Other emergency medicine in Dallas
- Farid DharamsiDallas$159K
- Gerald DelkDallas$60K
- Bradford BellardDallas$22K
- Robert SimonsonDallas$22K
- Betty YangDallas$21K
- James DetienneDallas$16K
- Deborah DiercksDallas$12K
- James LillyDallas$7K
- Kevin YavorcikDallas$6K
- John McKinneyTyler$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.